Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Cumulative Proton Pump Inhibitor Use with Prostate Cancer Risk and Outcomes: A Population-Based Cohort Study.

Cancer research communicationsĀ·2026
Same author

Evaluation of lighted catheter phototherapy in endoscopic treatment of urethral strictures: a rabbit pilot study.

International urology and nephrologyĀ·2026
Same author

Tumour-infiltrating adipocyte-derived 12,13-DiHOME subverts CD8<sup>+</sup> T cell immunity in pancreatic ductal adenocarcinoma by promoting PPARĪ³-mediated ferritinophagy and tumour-associated neutrophil ferroptosis.

GutĀ·2026
Same author

Gut Microbiota Regulates Systemic Inflammatory Response and Compensatory Anti-Inflammatory Response Syndromes by Targeting PF4<sup>+</sup> Macrophages in Acute Pancreatitis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)Ā·2026
Same author

Bacterial siderophore suppresses host genetic disorders of hyperactivated Ras by limiting iron deficiency that inhibits growth factor expression.

Cell reportsĀ·2026
Same author

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.

The oncologistĀ·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

CancersĀ·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

CancersĀ·2026
Same journal

Correction: PeƱalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

CancersĀ·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

CancersĀ·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

CancersĀ·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

CancersĀ·2026
See all related articles

Related Experiment Video

Updated: Nov 3, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer.

Stephanie Gleicher1, Baylee A Porter1,2, Disharee Nath1,2

  • 1Department of Urology, SUNY Upstate Medical University, 750 East Adams Str., Syracuse, NY 13010, USA.

Cancers
|June 2, 2021
PubMed
Summary
This summary is machine-generated.

Biochemical recurrence affects one-third of men treated for prostate cancer. This review covers current and novel therapies for non-metastatic castrate-resistant prostate cancer (nmCRPC) to delay disease progression.

Keywords:
STAT3castrate resistanceclinical trialepithelial mesenchymal transitionnon-metastatic CRPCprostate cancer

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.6K

Related Experiment Videos

Last Updated: Nov 3, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.6K

Area of Science:

  • Oncology
  • Urology
  • Medical Research

Background:

  • Biochemical recurrence is common after localized prostate cancer treatment.
  • Androgen deprivation therapy (ADT) is standard, but resistance develops.
  • Castrate-resistant prostate cancer (CRPC) can progress to metastatic disease (mCRPC).

Purpose of the Study:

  • To review current therapies for non-metastatic CRPC (nmCRPC).
  • To explore novel therapeutics and pathway strategies for nmCRPC.
  • To identify opportunities for early intervention in nmCRPC.

Main Methods:

  • Literature review of existing nmCRPC treatments.
  • Analysis of emerging therapeutic targets and pathways.
  • Discussion of clinical trial data for novel agents.

Main Results:

  • Several established therapies exist for nmCRPC.
  • Numerous novel agents and strategies are under investigation.
  • Early intervention in nmCRPC shows promise for delaying progression.

Conclusions:

  • nmCRPC represents a critical window for therapeutic intervention.
  • Novel approaches are expanding treatment options for nmCRPC patients.
  • Further research is needed to optimize nmCRPC management.